Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg

effects in mixed dyslipidemia

Kevin C. Maki, Barry C. Lubin, Matthew S. Reeves, Mary R. Dicklin, William Harris

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0%, -40.8%, -34.9%), low-density lipoprotein cholesterol (-48.0%, -35.5%, -38.0%), total cholesterol (TC) (-42.6%, -31.9%, -27.1%), the TC/HDL-C ratio (-52.9%, -44.3%, -36.2%), and apolipoprotein B (-42.6%, -32.6%, -30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P 

Original languageEnglish (US)
Pages (from-to)33-38
Number of pages6
JournalJournal of Clinical Lipidology
Volume3
Issue number1
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Simvastatin
Dyslipidemias
Prescriptions
Esters
Acids
Placebos
Lipids
Apolipoproteins B
Double-Blind Method
LDL Cholesterol
Cross-Over Studies
HDL Cholesterol
Cholesterol

Keywords

  • Dyslipidemia
  • Hypercholesterolemia
  • Omega-3 fatty acids
  • Statins
  • Triglycerides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg : effects in mixed dyslipidemia. / Maki, Kevin C.; Lubin, Barry C.; Reeves, Matthew S.; Dicklin, Mary R.; Harris, William.

In: Journal of Clinical Lipidology, Vol. 3, No. 1, 02.2009, p. 33-38.

Research output: Contribution to journalArticle

Maki, Kevin C. ; Lubin, Barry C. ; Reeves, Matthew S. ; Dicklin, Mary R. ; Harris, William. / Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg : effects in mixed dyslipidemia. In: Journal of Clinical Lipidology. 2009 ; Vol. 3, No. 1. pp. 33-38.
@article{555446a33b1b4e22a846840a796dc768,
title = "Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia",
abstract = "Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0{\%}, -40.8{\%}, -34.9{\%}), low-density lipoprotein cholesterol (-48.0{\%}, -35.5{\%}, -38.0{\%}), total cholesterol (TC) (-42.6{\%}, -31.9{\%}, -27.1{\%}), the TC/HDL-C ratio (-52.9{\%}, -44.3{\%}, -36.2{\%}), and apolipoprotein B (-42.6{\%}, -32.6{\%}, -30.5{\%}). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P ",
keywords = "Dyslipidemia, Hypercholesterolemia, Omega-3 fatty acids, Statins, Triglycerides",
author = "Maki, {Kevin C.} and Lubin, {Barry C.} and Reeves, {Matthew S.} and Dicklin, {Mary R.} and William Harris",
year = "2009",
month = "2",
doi = "10.1016/j.jacl.2008.12.007",
language = "English (US)",
volume = "3",
pages = "33--38",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg

T2 - effects in mixed dyslipidemia

AU - Maki, Kevin C.

AU - Lubin, Barry C.

AU - Reeves, Matthew S.

AU - Dicklin, Mary R.

AU - Harris, William

PY - 2009/2

Y1 - 2009/2

N2 - Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0%, -40.8%, -34.9%), low-density lipoprotein cholesterol (-48.0%, -35.5%, -38.0%), total cholesterol (TC) (-42.6%, -31.9%, -27.1%), the TC/HDL-C ratio (-52.9%, -44.3%, -36.2%), and apolipoprotein B (-42.6%, -32.6%, -30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P 

AB - Background: Prescription omega-3 acid ethyl esters (P-OM3) plus simvastatin 20 and 40 mg/day improves lipids in subjects with mixed dyslipidemia, but no previous studies have examined P-OM3 with the maximum prescribed dose of simvastatin (80 mg). Objective: To assess the effects of P-OM3 + simvastatin 80 mg versus P-OM3 + simvastatin 20 mg or placebo + simvastatin 20 mg on non-high-density lipoprotein cholesterol (non-HDL-C) and other lipid concentrations. Methods: Subjects with mixed dyslipidemia who had completed a 12-week double-blind crossover study of simvastatin 20 mg/day + either placebo or P-OM3 4 g/day were enrolled. An analysis (n = 14) was performed following the first six weeks of the extension, during which all subjects received open-label P-OM3 + open-label simvastatin 80 mg/day. Results: P-OM3 + simvastatin 80 mg resulted in significantly larger reductions from baseline (P <.05 for all) versus P-OM3 + simvastatin 20 mg and placebo + simvastatin 20 mg, respectively, for non-HDL-C (-51.0%, -40.8%, -34.9%), low-density lipoprotein cholesterol (-48.0%, -35.5%, -38.0%), total cholesterol (TC) (-42.6%, -31.9%, -27.1%), the TC/HDL-C ratio (-52.9%, -44.3%, -36.2%), and apolipoprotein B (-42.6%, -32.6%, -30.5%). P-OM3 + simvastatin (80- and 20-mg doses, respectively) resulted in significantly larger changes from baseline (P 

KW - Dyslipidemia

KW - Hypercholesterolemia

KW - Omega-3 fatty acids

KW - Statins

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=59249107912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249107912&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2008.12.007

DO - 10.1016/j.jacl.2008.12.007

M3 - Article

VL - 3

SP - 33

EP - 38

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 1

ER -